Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that data from its randomized Phase 2/3 COMPANION-002 trial evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer will be presented orally at the upcoming ESMO Congress. This presentation highlights clinical progress in their bispecific antibody program targeting DLL4 and VEGF-A …